CL2020002939A1 - Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas - Google Patents
Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosasInfo
- Publication number
- CL2020002939A1 CL2020002939A1 CL2020002939A CL2020002939A CL2020002939A1 CL 2020002939 A1 CL2020002939 A1 CL 2020002939A1 CL 2020002939 A CL2020002939 A CL 2020002939A CL 2020002939 A CL2020002939 A CL 2020002939A CL 2020002939 A1 CL2020002939 A1 CL 2020002939A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- thiazol
- sensitization
- diseases associated
- nerve fibers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere al uso de compuestos de benzamida sustituida con 1,3-tiazol-2-ilo de la fórmula general (I) tal como se ha descripto y definido en la presente, a composiciones farmacéuticas y combinaciones que comprenden esos compuestos para el tratamiento o la profilaxis de enfermedades asociadas a la sensibilización de fibras nerviosas, en particular para el tratamiento y la profilaxis de la Tos Crónica (TC), la Fibrosis Pulmonar Idiopática (FPI), la Enfermedad Pulmonar Obstructiva Crónica (EPOC), y el asma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18172409 | 2018-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002939A1 true CL2020002939A1 (es) | 2021-03-05 |
Family
ID=62186254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002939A CL2020002939A1 (es) | 2018-05-15 | 2020-11-12 | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210220358A1 (es) |
EP (1) | EP3793554A1 (es) |
JP (1) | JP2021523919A (es) |
KR (1) | KR20210009341A (es) |
CN (1) | CN112334132A (es) |
AU (1) | AU2019269049A1 (es) |
BR (1) | BR112020022553A2 (es) |
CA (1) | CA3100099A1 (es) |
CL (1) | CL2020002939A1 (es) |
EA (1) | EA202092678A1 (es) |
JO (1) | JOP20200286A1 (es) |
MA (1) | MA52618A (es) |
MX (1) | MX2020012202A (es) |
SG (1) | SG11202011010YA (es) |
TW (1) | TWI780329B (es) |
WO (1) | WO2019219674A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20180227A1 (es) | 2014-12-09 | 2018-01-31 | Bayer Ag | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
CN113559104A (zh) | 2018-10-05 | 2021-10-29 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
AU2021282039A1 (en) * | 2020-05-25 | 2022-12-01 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Arylformamide compound and preparation method and medical use thereof |
WO2022068930A1 (zh) * | 2020-09-30 | 2022-04-07 | 武汉人福创新药物研发中心有限公司 | 苯甲酰胺类化合物及其用途 |
WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
CN101981003B (zh) * | 2008-02-29 | 2014-07-02 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
MY195728A (en) | 2013-08-23 | 2023-02-07 | Afferent Pharmaceuticals Inc | Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough |
PE20180227A1 (es) | 2014-12-09 | 2018-01-31 | Bayer Ag | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
JP6877441B2 (ja) * | 2015-09-29 | 2021-05-26 | アファレント ファーマシューティカルズ インコーポレイテッド | 咳の処置における使用のためのジアミノピリミジンp2x3及びp2x2/3受容体修飾因子 |
BR112020022340A2 (pt) * | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
-
2019
- 2019-05-14 CA CA3100099A patent/CA3100099A1/en active Pending
- 2019-05-14 SG SG11202011010YA patent/SG11202011010YA/en unknown
- 2019-05-14 US US17/055,488 patent/US20210220358A1/en not_active Abandoned
- 2019-05-14 TW TW108116606A patent/TWI780329B/zh active
- 2019-05-14 EP EP19723792.8A patent/EP3793554A1/en not_active Withdrawn
- 2019-05-14 CN CN201980042853.2A patent/CN112334132A/zh active Pending
- 2019-05-14 EA EA202092678A patent/EA202092678A1/ru unknown
- 2019-05-14 KR KR1020207035583A patent/KR20210009341A/ko not_active Application Discontinuation
- 2019-05-14 AU AU2019269049A patent/AU2019269049A1/en active Pending
- 2019-05-14 JO JOP/2020/0286A patent/JOP20200286A1/ar unknown
- 2019-05-14 BR BR112020022553-3A patent/BR112020022553A2/pt unknown
- 2019-05-14 MX MX2020012202A patent/MX2020012202A/es unknown
- 2019-05-14 WO PCT/EP2019/062332 patent/WO2019219674A1/en unknown
- 2019-05-14 JP JP2020564269A patent/JP2021523919A/ja active Pending
- 2019-05-14 MA MA052618A patent/MA52618A/fr unknown
-
2020
- 2020-11-12 CL CL2020002939A patent/CL2020002939A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202011010YA (en) | 2020-12-30 |
AU2019269049A1 (en) | 2020-11-26 |
CA3100099A1 (en) | 2019-11-21 |
CN112334132A (zh) | 2021-02-05 |
BR112020022553A2 (pt) | 2021-02-02 |
JP2021523919A (ja) | 2021-09-09 |
TWI780329B (zh) | 2022-10-11 |
US20210220358A1 (en) | 2021-07-22 |
TW201946924A (zh) | 2019-12-16 |
JOP20200286A1 (ar) | 2020-11-09 |
MX2020012202A (es) | 2021-01-29 |
EA202092678A1 (ru) | 2021-04-12 |
WO2019219674A1 (en) | 2019-11-21 |
EP3793554A1 (en) | 2021-03-24 |
KR20210009341A (ko) | 2021-01-26 |
MA52618A (fr) | 2021-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002939A1 (es) | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas | |
CO2021017031A2 (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3) | |
CL2019002103A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa. | |
ECSP088335A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
MX2020005909A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo. | |
PA8774101A1 (es) | Compuesto de pirmidina | |
CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
BR112015018726A2 (pt) | composições compreendendo gougerotina e um fungicida | |
UY32938A (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
CL2020002940A1 (es) | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilización de las fibras nerviosas | |
BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
BR112014013958A2 (pt) | ácidos piperidinila naftilacéticos | |
CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
BR112021019802A2 (pt) | Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial | |
CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
BR112022002772A2 (pt) | Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso | |
PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease |